Acceleron Pharma Inc.
Methods of treating a sclerotic disorder by administering a transforming growth factor beta receptor type II fusion polypeptide

Abstract:

In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T.beta.RII polypeptide useful to selectively antagonize a T.beta.RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF.beta. associated disorders.